Page 8 - ஃபின்லே நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Marc Frank 3 minute read A nurse prepares a dose of the Soberana 02 vaccine during its clinical trials at a hospital amid concerns about the spread of the coronavirus disease (COVID-19) in Havana, Cuba, June 29, 2021. REUTERS/Alexandre Meneghini HAVANA, July 8 (Reuters) - Cuba said on Thursday its two-shot Soberana 2 vaccine, delivered with a booster called Soberana Plus, had proven 91.2% effective in late stage clinical trials against the coronavirus, following similar news about its Abdala vaccine. The announcement came from state-run biopharmaceutical corporation BioCubaFarma, which oversees the Finlay Institute, the maker of Soberana 2, and the Center for Genetic Engineering and Biotechnology, the producer of Abdala. Last month, Abdala was found to have a 92.28% efficacy.

United statesCiudad de la habanaRepublic ofJose martiSantiago de cubaMarc frankThomson reuters trust principlesFinlay instituteWorld health organizationSoberana plusGenetic engineeringLatin americaWorld healthThomson reuters trustஒன்றுபட்டது மாநிலங்களில்யடட டி லா ஹபனா